Kura Oncology, Inc(KURA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

KURA Kura Oncology, Inc

交易中 03-23 15:52:40 EDT

8.31

+0.05

+0.61%

最高8.49	最低8.05	成交量83.33万
今开8.39	昨收8.26	日振幅5.27%
总市值7.34亿	流通市值5.32亿	总股本8,833万
成交额690.21万	换手率1.30%	流通股本6,399万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"KURA","market":"US","secType":"STK","nameCN":"Kura Oncology, Inc","latestPrice":8.31,"timestamp":1774295556021,"preClose":8.26,"halted":0,"volume":833252,"delay":0,"changeRate":0.0060532687651332585,"floatShares":63985582,"shares":88329800,"eps":-3.178361,"marketStatus":"交易中","change":0.05,"latestTime":"03-23 15:52:40 EDT","open":8.39,"high":8.485,"low":8.05,"amount":6902082.9576159995,"amplitude":0.052663,"askPrice":8.33,"askSize":580,"bidPrice":8.31,"bidSize":794,"shortable":3,"etf":0,"ttmEps":-3.178361,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1774296000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1446699600000,"exchange":"NASDAQ","adjPreClose":8.26,"preHourTrading":{"tag":"盘前","latestPrice":8.43,"preClose":8.26,"latestTime":"08:32 EDT","volume":514,"amount":4286.560054,"timestamp":1774269173450,"change":0.17,"changeRate":0.020581,"amplitude":0.025424},"postHourTrading":{"tag":"盘后","latestPrice":8.26,"preClose":8.26,"latestTime":"19:40 EDT","volume":660554,"amount":5456174.7664,"timestamp":1774050027207,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.682241,"impliedVol":0.5641,"impliedVolPercentile":0.3068},"requestUrl":"/m/hq/s/KURA","defaultTab":"news","newsList":[{"id":"1113707869","title":"Kura Oncology Inc - Komzifti与Venetoclax和Azacitidine三重组合在新诊断和复发/难治性设置中耐受良好","url":"https://stock-news.laohu8.com/highlight/detail?id=1113707869","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113707869?lang=zh_cn&edition=full","pubTime":"2025-12-08 23:43","pubTimestamp":1765208596,"startTime":"0","endTime":"0","summary":"Kura Oncology Inc - Komzifti与Venetoclax和Azacitidine三重组合在新诊断和复发/难治性设置中耐受良好","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KURA","BK4139","BK4505"],"gpt_icon":0},{"id":"1142603721","title":"美国首次商业销售Komzifti™触发Kura Oncology与Kyowa Kirin合作许可协议下的1.35亿美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1142603721","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142603721?lang=zh_cn&edition=full","pubTime":"2025-12-02 21:03","pubTimestamp":1764680589,"startTime":"0","endTime":"0","summary":"美国首次商业销售Komzifti™触发Kura Oncology与Kyowa Kirin合作许可协议下的1.35亿美元里程碑付款","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","KURA"],"gpt_icon":0},{"id":"2586921107","title":"Kura Oncology, Inc.盘中异动 股价大涨5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586921107","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586921107?lang=zh_cn&edition=full","pubTime":"2025-11-27 04:28","pubTimestamp":1764188885,"startTime":"0","endTime":"0","summary":"北京时间2025年11月27日04时28分，Kura Oncology, Inc.股票出现波动，股价快速上涨5.09%。Kura Oncology, Inc.股票所在的生物技术行业中，整体涨幅为0.62%。Kura Oncology, Inc.公司简介：Kura Oncology Inc 是一家临床阶段的生物制药公司，致力于实现精准药物治疗癌症的承诺。消息层面，截至04时28分，《LifeSci Capital维持Kura Oncology买入评级，维持目标价28美元》资讯为影响Kura Oncology, Inc.的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251127042805951c3885&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251127042805951c3885&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4139","KURA"],"gpt_icon":0},{"id":"1115337740","title":"Kura Oncology高管表示，Komzifti每日固定剂量一个月的美国上市价格为48,500美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1115337740","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115337740?lang=zh_cn&edition=full","pubTime":"2025-11-14 01:55","pubTimestamp":1763056510,"startTime":"0","endTime":"0","summary":"Kura Oncology高管表示，Komzifti每日固定剂量一个月的美国上市价格为48,500美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KURA","BK4139","BK4505"],"gpt_icon":0},{"id":"1160581625","title":"Kura Oncology高管表示已与FDA展开对话，为批准后改进标签做准备 - 电话会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1160581625","media":"美股速递","labels":["executive","policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160581625?lang=zh_cn&edition=full","pubTime":"2025-11-14 01:47","pubTimestamp":1763056030,"startTime":"0","endTime":"0","summary":"Kura Oncology高管表示已与FDA展开对话，为批准后改进标签做准备 - 电话会议","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","KURA"],"gpt_icon":0},{"id":"1130437443","title":"Kura Oncology和Kyowa Kirin宣布Komzifti™（Ziftomenib）获得FDA批准，成为首个也是唯一每日一次的针对成人复发或难治性Npm1突变急性髓性白血病的靶向治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1130437443","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130437443?lang=zh_cn&edition=full","pubTime":"2025-11-13 23:52","pubTimestamp":1763049141,"startTime":"0","endTime":"0","summary":"Kura Oncology和Kyowa Kirin宣布Komzifti™（Ziftomenib）获得FDA的批准，成为首个也是唯一每日一次的针对成人复发或难治性Npm1突变急性髓性白血病的靶向治疗。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KURA","BK4505","BK4139"],"gpt_icon":0},{"id":"2581672797","title":"Kura Oncology, Inc.盘中异动 股价大跌6.70%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581672797","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581672797?lang=zh_cn&edition=full","pubTime":"2025-11-04 22:32","pubTimestamp":1762266728,"startTime":"0","endTime":"0","summary":"北京时间2025年11月04日22时32分，Kura Oncology, Inc.股票出现异动，股价快速下挫6.70%。Kura Oncology, Inc.股票所在的生物技术行业中，整体跌幅为0.91%。其相关个股中，Terns Pharmaceuticals, Inc.、Tevogen Bio Holdings Inc C/Wts 14/02/2029 、Psyence Biomedical Ltd C/Wts 25/01/2029涨幅较大，Artelo Biosciences, Inc.、Abpro Holdings, Inc、Biomx Inc.较为活跃，换手率分别为264.01%、82.32%、63.21%，振幅较大的相关个股有Abpro Holdings, Inc、Revelation Biosciences Inc C/Wts 10/01/2027 、Nuvation Bio Inc.，振幅分别为17.08%、13.56%、12.57%。Kura Oncology, Inc.公司简介：Kura Oncology Inc 是一家临床阶段的生物制药公司，致力于实现精准药物治疗癌症的承诺。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251104223209a6e0b5f1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251104223209a6e0b5f1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4139","KURA"],"gpt_icon":0},{"id":"1127287316","title":"Kura Oncology Inc：我们相信截至2025年9月30日的现金、现金等价物和短期投资将足以覆盖到2027年的运营费用","url":"https://stock-news.laohu8.com/highlight/detail?id=1127287316","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127287316?lang=zh_cn&edition=full","pubTime":"2025-11-04 19:42","pubTimestamp":1762256576,"startTime":"0","endTime":"0","summary":"Kura Oncology Inc：我们相信截至2025年9月30日的现金、现金等价物和短期投资将足以覆盖到2027年的运营费用","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KURA","BK4139","BK4505"],"gpt_icon":0},{"id":"1179163936","title":"Kura Oncology获3000万美元开发里程碑支付，推进Ziftomenib AML项目与Kyowa Kirin的合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1179163936","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179163936?lang=zh_cn&edition=full","pubTime":"2025-10-24 19:03","pubTimestamp":1761303798,"startTime":"0","endTime":"0","summary":"Kura Oncology获3000万美元开发里程碑支付，推进Ziftomenib AML项目与Kyowa Kirin的合作","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KURA","BK4139","BK4505"],"gpt_icon":0},{"id":"2574973001","title":"Kura Oncology, Inc.盘中异动 早盘大幅上涨5.04%报9.91美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2574973001","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574973001?lang=zh_cn&edition=full","pubTime":"2025-10-08 22:37","pubTimestamp":1759934279,"startTime":"0","endTime":"0","summary":"北京时间2025年10月08日22时37分，Kura Oncology, Inc.股票出现异动，股价大幅上涨5.04%。截至发稿，该股报9.91美元/股，成交量22.2946万股，换手率0.26%，振幅3.50%。Kura Oncology, Inc.股票所在的生物技术行业中，整体涨幅为0.26%。Kura Oncology, Inc.公司简介：Kura Oncology Inc 是一家临床阶段的生物制药公司，致力于实现精准药物治疗癌症的承诺。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251008223759a6b0dc46&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251008223759a6b0dc46&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KURA","BK4139","BK4505"],"gpt_icon":0},{"id":"2572465301","title":"Kura Oncology, Inc.盘中异动 大幅上涨5.03%报9.60美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2572465301","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2572465301?lang=zh_cn&edition=full","pubTime":"2025-10-03 23:17","pubTimestamp":1759504636,"startTime":"0","endTime":"0","summary":"北京时间2025年10月03日23时17分，Kura Oncology, Inc.股票出现异动，股价大幅拉升5.03%。Kura Oncology, Inc.股票所在的生物技术行业中，整体涨幅为0.35%。其相关个股中，Alto Neuroscience, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 、Nrx Pharmaceuticals Inc C/Wts 24/05/2026 涨幅较大，Alto Neuroscience, Inc.、Palisade Bio, Inc.、Ovid Therapeutics Inc.较为活跃，换手率分别为145.94%、111.32%、59.66%，振幅较大的相关个股有Alto Neuroscience, Inc.、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 、Briacell Therapeutics Corp C/Wts ，振幅分别为55.10%、32.29%、32.25%。Kura Oncology, Inc.公司简介：Kura Oncology Inc 是一家临床阶段的生物制药公司，致力于实现精准药物治疗癌症的承诺。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251003231717971e8ca7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251003231717971e8ca7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","KURA","BK4139"],"gpt_icon":0},{"id":"1139652548","title":"Kura Oncology与Kyowa Kirin启动临床试验，评估在新诊断急性髓性白血病患者中对Npm1和Flt3突变的双重抑制效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1139652548","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139652548?lang=zh_cn&edition=full","pubTime":"2025-10-01 19:01","pubTimestamp":1759316509,"startTime":"0","endTime":"0","summary":"Kura Oncology与Kyowa Kirin宣布启动一项临床试验，该试验将评估在新诊断急性髓性白血病(AML)患者中对Npm1和Flt3突变进行双重抑制的治疗效果。\n这项合作研究旨在探索针对这两个关键突变靶点的联合治疗策略，为急性髓性白血病患者提供新的治疗选择。该临床试验将重点关注新确诊的AML患者群体，通过同时抑制Npm1和Flt3突变来评估治疗的安全性和有效性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","KURA"],"gpt_icon":0},{"id":"1100188247","title":"Kura Oncology与Kyowa Kirin宣布Ziftomenib治疗一线急性髓系白血病关键性3期Komet-017试验首位患者完成给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1100188247","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100188247?lang=zh_cn&edition=full","pubTime":"2025-09-30 04:01","pubTimestamp":1759176083,"startTime":"0","endTime":"0","summary":"Kura Oncology与Kyowa Kirin宣布，针对一线急性髓系白血病（AML）的Ziftomenib关键性3期Komet-017试验已完成首位患者给药。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KURA","BK4139","BK4505"],"gpt_icon":0},{"id":"2517162278","title":"瑞银：维持Kura Oncology(KURA.US)评级，由买入调整至买入评级, 目标价由27.00美元调整至14.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517162278","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517162278?lang=zh_cn&edition=full","pubTime":"2025-03-07 00:05","pubTimestamp":1741277144,"startTime":"0","endTime":"0","summary":"瑞银：维持Kura Oncology(KURA.US)评级，由买入调整至买入评级, 目标价由27.00美元调整至14.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/07000548577058.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["KURA"],"gpt_icon":0},{"id":"2516169663","title":"Kura Oncology, Inc.盘中异动 下午盘急速跳水5.06%报7.32美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516169663","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516169663?lang=zh_cn&edition=full","pubTime":"2025-03-04 04:27","pubTimestamp":1741033650,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日04时27分，Kura Oncology, Inc.股票出现波动，股价快速跳水5.06%。截至发稿，该股报7.32美元/股，成交量75.0327万股，换手率0.93%，振幅7.33%。Kura Oncology, Inc.股票所在的生物技术行业中，整体涨幅为0.02%。Kura Oncology, Inc.公司简介：Kura Oncology Inc 是一家临床阶段的生物制药公司，致力于发现和开发用于治疗实体肿瘤和血癌的治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304042731989a5f18&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304042731989a5f18&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KURA","BK4139","BK4505"],"gpt_icon":0},{"id":"2516548051","title":"Kura Oncology, Inc.2024财年实现净利润-1.74亿美元，同比减少13.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516548051","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516548051?lang=zh_cn&edition=full","pubTime":"2025-03-03 00:01","pubTimestamp":1740931271,"startTime":"0","endTime":"0","summary":"3月3日，Kura Oncology, Inc.公布财报，公告显示公司2024财年净利润为-1.74亿美元，同比减少13.73%；其中营业收入为53.88百万美元，每股基本收益为-2.02美元。从资产负债表来看，Kura Oncology, Inc.总负债6.27亿美元，其中短期债务4.49百万美元，资产负债比为1.67，流动比率为0.10。机构评级：截至2025年3月3日，当前有12家机构对Kura Oncology, Inc.目标价做出预测，其中目标均价为27.75美元，其中最低目标价为10.00美元，最高目标价为40.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000150abe4acd2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000150abe4acd2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KURA"],"gpt_icon":0},{"id":"1110051286","title":"异动解读 | Kura Oncology财报超预期,盘后股价大涨6.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=1110051286","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110051286?lang=zh_cn&edition=full","pubTime":"2025-02-27 05:53","pubTimestamp":1740606783,"startTime":"0","endTime":"0","summary":"Kura Oncology公司(KURA)在2025年2月26日星期三的盘后交易中股价大涨6.69%,引起市场广泛关注。\n\n公司发布的最新财报数据显示,其第四季度GAAP每股亏损为0.22美元,优于分析师一致预期的0.65美元亏损,超出预期幅度高达66.15%;同时,公司季度销售额达到5388万美元,远高于市场预期的850万美元,增长幅度超过533.92%。\n\n财报数据明显超出市场预期,反映出公司业绩和发展势头良好,投资者对此反应积极,推动了公司股价在盘后市场的大涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["KURA"],"gpt_icon":0},{"id":"1132024829","title":"Kura Oncology第四季度GAAP每股亏损$(0.22)优于预期$(0.65)，销售额达$53.88M远超预期$8.50M","url":"https://stock-news.laohu8.com/highlight/detail?id=1132024829","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132024829?lang=zh_cn&edition=full","pubTime":"2025-02-27 05:36","pubTimestamp":1740605792,"startTime":"0","endTime":"0","summary":"Kura Oncology报告称，其季度每股亏损$，优于分析师一致预期的$，超出预期66.15%。相比去年同期每股亏损$，同比改善60%。公司报告季度销售额为$53.88M，远超分析师预期的$8.50M，增长533.92%。以上内容来自Benzinga Earnings专栏，原文如下：Kura Oncology  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 66.15 percent. This is a 60 percent increase over losses of $ per share from the same period last year.  The company reported quarterly sales of $53.88 million which beat the analyst consensus estimate of $8.50 million by 533.92 percent.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Kura Oncology第四季度GAAP每股亏损$(0.22)优于预期$(0.65)，销售额达$53.88M远超预期$8.50M","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KURA"],"gpt_icon":0},{"id":"2510332698","title":"Kura Oncology, Inc.盘中异动 股价大跌5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510332698","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510332698?lang=zh_cn&edition=full","pubTime":"2025-02-12 00:49","pubTimestamp":1739292574,"startTime":"0","endTime":"0","summary":"北京时间2025年02月12日00时49分，Kura Oncology, Inc.股票出现异动，股价快速下挫5.01%。Kura Oncology, Inc.股票所在的生物技术行业中，整体跌幅为1.45%。其相关个股中，Omega Therapeutics, Inc.、Lipella Pharmaceuticals Inc.、Oramed Pharmaceuticals Inc.涨幅较大，Lipella Pharmaceuticals Inc.、Ocean Biomedical, Inc.、Dominari Holdings Inc.较为活跃，换手率分别为2984.89%、1321.42%、435.90%，振幅较大的相关个股有Omega Therapeutics, Inc.、Ocean Biomedical, Inc.、Dominari Holdings Inc.，振幅分别为143.33%、59.46%、58.60%。Kura Oncology, Inc.公司简介：Kura Oncology Inc 是一家临床阶段的生物制药公司，致力于发现和开发用于治疗实体肿瘤和血癌的治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502120049359881d4b8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502120049359881d4b8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","KURA","BK4505"],"gpt_icon":0},{"id":"2509272661","title":"Kura Oncology, Inc.盘中异动 股价大跌12.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509272661","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509272661?lang=zh_cn&edition=full","pubTime":"2025-02-06 22:32","pubTimestamp":1738852335,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日22时32分，Kura Oncology, Inc.股票出现波动，股价急速跳水12.04%。Kura Oncology, Inc.股票所在的生物技术行业中，整体跌幅为0.02%。其相关个股中，Lipella Pharmaceuticals Inc.、Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Immatics N V C/Wts 01/07/2025 涨幅较大，Lipella Pharmaceuticals Inc.、Transcode Therapeutics, Inc.、Silexion Therapeutics Corp较为活跃，换手率分别为3890.21%、340.23%、114.95%，振幅较大的相关个股有Lipella Pharmaceuticals Inc.、Rani Therapeutics Holdings, Inc.、Relmada Therapeutics, Inc.，振幅分别为33.33%、15.97%、14.26%。Kura Oncology, Inc.公司简介：Kura Oncology Inc 是一家临床阶段的生物制药公司，致力于发现和开发用于治疗实体肿瘤和血癌的治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206223215abc4d4a6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206223215abc4d4a6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4505","KURA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kuraoncology.com","stockEarnings":[{"period":"1week","weight":-0.0451},{"period":"1month","weight":-0.0271},{"period":"3month","weight":-0.1606},{"period":"6month","weight":0.0012},{"period":"1year","weight":0.0522},{"period":"ytd","weight":-0.205}],"compareEarnings":[{"period":"1week","weight":-0.0207},{"period":"1month","weight":-0.055},{"period":"3month","weight":-0.047},{"period":"6month","weight":-0.0228},{"period":"1year","weight":0.1469},{"period":"ytd","weight":-0.0489}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Kura Oncology, Inc.最初于2007年11月在特拉华州注册成立。他们是一家临床阶段的生物制药公司，致力于实现精准药物治疗癌症的前景。他们的产品线由针对癌症信号通路的小分子候选产品组成，在这些信号通路中，有很强的科学和临床理由来改善结果，他们打算将其与分子或细胞诊断相结合，以确定最有可能对治疗做出反应的患者。他们正在对三种候选产品进行临床试验：齐夫托米尼、替比法尼和KO-2806。","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.002309},{"month":2,"riseRate":0.545455,"avgChangeRate":0.031825},{"month":3,"riseRate":0.545455,"avgChangeRate":-0.032071},{"month":4,"riseRate":0.2,"avgChangeRate":-0.031764},{"month":5,"riseRate":0.5,"avgChangeRate":0.015121},{"month":6,"riseRate":0.5,"avgChangeRate":0.037607},{"month":7,"riseRate":0.5,"avgChangeRate":0.037366},{"month":8,"riseRate":0.5,"avgChangeRate":0.066679},{"month":9,"riseRate":0.5,"avgChangeRate":0.12103},{"month":10,"riseRate":0.3,"avgChangeRate":-0.077132},{"month":11,"riseRate":0.8,"avgChangeRate":0.052179},{"month":12,"riseRate":0.454545,"avgChangeRate":0.00367}],"exchange":"NASDAQ","name":"Kura Oncology, Inc","nameEN":"Kura Oncology"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kura Oncology, Inc(KURA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Kura Oncology, Inc(KURA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Kura Oncology, Inc,KURA,Kura Oncology, Inc股票,Kura Oncology, Inc股票老虎,Kura Oncology, Inc股票老虎国际,Kura Oncology, Inc行情,Kura Oncology, Inc股票行情,Kura Oncology, Inc股价,Kura Oncology, Inc股市,Kura Oncology, Inc股票价格,Kura Oncology, Inc股票交易,Kura Oncology, Inc股票购买,Kura Oncology, Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kura Oncology, Inc(KURA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Kura Oncology, Inc(KURA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}